| Christopher Peetz |
Christopher Peetz is the founder of Mirum Pharmaceuticals, Inc. (founded in 2018) where he holds the title of Chief Executive Officer & Director. He is currently the Chief Executive Officer at Satiogen Pharmaceuticals, Inc. and an Independent Director at Alpine Immune Sciences, Inc. Mr. Peetz's former positions include being the Chief Executive Officer at Flashlight Therapeutics, Inc. from 2014 to 2016, Senior Director-Corporate Development & Strategy at Onyx Pharmaceuticals, Inc. from 2007 to 2012, and Vice President-Finance & Development at SillaJen Biotherapeutics, Inc. from 2012 to 2014. He also held the position of Chief Financial Officer & Head-Development at Tobira Therapeutics, Inc. from 2014 to 2016. Mr. Peetz received his undergraduate degree from Washington University in St. Louis and an MBA from Stanford Graduate School of Business. |
| Jean-Luc Samuel Francois Girardet |
Jean-Luc Samuel Francois Girardet is currently the Senior Vice President-Pharmaceutical Sciences at Brii Biosciences Ltd. (China) since 2018. He is also currently the Senior Vice President-Technical Operations at Mirum Pharmaceuticals, Inc. Previously, Dr. Girardet worked as the Vice President-Research Operations at Ardea Biosciences, Inc. Dr. Girardet completed his undergraduate degree in 1991 and his doctorate degree in 1995 from Université de Montpellier. |
| Pamela Vig |
Pamela Vig is currently the Chief Scientific Officer & Head-Research at Mirum Pharmaceuticals, Inc. She previously worked as the Director-Clinical Development at Shire ViroPharma, Inc., Associate Director-European Medical Affairs at Idenix Pharmaceuticals LLC, Director-Global Medical Affairs at Johnson & Johnson Ltd., Clinical Research Officer at Chiron Corp. and Gilead Sciences, Inc., Associate VP-Clinical Research & Development at Presidio Pharmaceuticals, Inc. and Allergan Ltd. (Ireland), Vice President-Clinical Research & Discovery at Tobira Therapeutics, Inc., and Chief Scientific Officer at Flashlight Therapeutics, Inc. Dr. Vig obtained her graduate and doctorate degrees from Imperial College London and her undergraduate degree from the University of Nevada. |
| Joanne M. Quan |
Joanne M. Quan is the founder of Nuvig Therapeutics, Inc. Currently, she is the Chief Medical Officer at Mirum Pharmaceuticals, Inc. Her former positions include Vice President-Clinical & Regulatory Affairs at Bayhill Therapeutics, Inc., Vice President-Clinical Development at Arena Pharmaceuticals, Inc., Vice President-w Product Clinical Development at InterMune, Inc., Director-Clinical Research at PathoGenesis Corp, Medical Director at Genentech, Inc., and Senior Director-Clinical Development at ALZA Corp. She has also served as the Chief Medical Officer at Eiger BioPharmaceuticals, Inc. Dr. Quan received her undergraduate degree from the University of California, Berkeley, and her doctorate from Stanford University School of Medicine. |
| Peter Radovich |
Peter Radovich is the President & Chief Operating Officer at Mirum Pharmaceuticals, Inc. He previously worked as the Senior Director & VP-Program Leadership at Onyx Pharmaceuticals, Inc. from 2004 to 2006. He also served as an Independent Director at Rain Oncology, Inc. from 2018 to 2024. Additionally, Mr. Radovich worked as a Principal at Chiron Corp. from 2004 to 2006 and as the Senior Vice President-Operations at Global Blood Therapeutics, Inc. from 2014 to 2020. He holds an MBA from the University of Washington and an undergraduate degree from Texas Christian University. |
| Eric Hands Claude Bjerkholt |
Eric Hands Claude Bjerkholt was the founder of LifeSpring Home Nutrition (founded in 1999) and Kenady LLC (founded in 1999), where he held the titles of President, Chief Executive & Financial Officer. Currently, Mr. Bjerkholt holds the position of Independent Director at Cerus Corp. (since 2018), Director at Aimmune Therapeutics UK Ltd. (since 2018), Independent Director at Surrozen, Inc. (since 2023), Independent Director at CalciMedica, Inc. (since 2023), and Chief Financial Officer at Mirum Pharmaceuticals, Inc. (since 2023). In the past, Mr. Bjerkholt has held positions such as Independent Director at StemCells, Inc. (2011-2016), Independent Director at Graybug Vision, Inc., Director at Round Table Pizza, Inc., Independent Director at Ambrx, Inc., Director at Corium International, Inc. (2015-2018), Director at Atara Biotherapeutics, Inc., Director at Structure Therapeutics, Inc., Chief Financial Officer & Senior Vice President at IntraBiotics Pharmaceuticals, Inc. (2002-2004), CFO, Secretary & EVP-Corporate Development at Sunesis Pharmaceuticals, Inc. (2012-2017), Chief Financial Officer at Aimmune Therapeutics, Inc. (2017-2020), and Vice President at J.P. Morgan & Co., Inc. (Delaware) (1990-1997). Mr. Bjerkholt's education includes an undergraduate degree from the University of Oslo and an MBA from Harvard Business School. |
| Lara Krupka-Longpre |
Lara Krupka-Longpre is currently the Chief Development Officer at Mirum Pharmaceuticals, Inc. She previously worked as the Chief Operating Officer at MedGenesis Therapeutix, Inc. and SillaJen Biotherapeutics, Inc. Additionally, she held the position of Vice President-Proposals & Contracts at PRA Health Sciences, Inc. Krupka-Longpre holds an MBA from Queen's University, an undergraduate degree from Cornell University, and a graduate degree from Harvard Medical School. |
| Paul K. Ross |
Paul K. Ross is currently the Chief Compliance Officer at Mirum Pharmaceuticals, Inc. He previously worked as a Director at United National Bancorp (New Jersey), Chief Compliance Officer & Vice President at Onyx Pharmaceuticals, Inc. and Horizon Pharmaceutical LLC, and Chief Compliance Officer at Raptor Pharmaceuticals, Inc. He was also a Member at Compliancestat LLC. Mr. Ross completed his undergraduate degree at the University of California, Santa Barbara and earned an MBA from the University of Phoenix. |
| Michael G. Grey |
Mike has been a Venture Partner with Pappas Capital since January 2010 and served as a member of the firm's Board of Advisors from 2004 to 2010. Mike currently serves as Chairman of Mirum Pharmaceuticals (a Pappas Ventures V portfolio company), as Executive Chair of Plexium, Sorriso Pharmaceuticals, Spruce Biosciences and Reneo Pharmaceuticals (a Pappas Ventures V portfolio company that he co-founded), and as a director for Horizon Therapeutics (NASDAQ: HZNP). In 2011, he spearheaded the founding of Lumena Pharmaceuticals (a Pappas Ventures IV portfolio company), and served as CEO until it was acquired by Shire plc in 2014. Prior to Lumena, Mike was President and CEO of Auspex Pharmaceuticals, and President and CEO of SGX Pharmaceuticals until its sale to Eli Lilly. Prior to joining SGX in 2001, Mike served as President and CEO of Trega Biosciences until its acquisition by Lion Bioscience. He also served as President of BioChem Therapeutics, the pharmaceutical arm of BioChem Pharma, from 1994 to 1998, and served as President and COO for Ansan during 1994. From 1974 to 1993, Mike served in various roles with Glaxo Holdings plc and Glaxo Inc., including positions as Vice President of Corporate Development and head of worldwide business development.
Mike previously served as CEO and subsequently Executive Chair of Amplyx Pharmaceuticals (a Pappas Ventures V portfolio company), which was acquired by Pfizer. He also previously served as a director for BioMarin Pharmaceutical (NASDAQ: BMRN), Mirati Therapeutics (NASDAQ: MRTX) (a Pappas Ventures III portfolio company), Balance Therapeutics (a Pappas Ventures IV portfolio company), Selventa (a Pappas Ventures II portfolio company), Biothera Pharmaceutical, Ziarco Pharma (acquired by Novartis), and three public companies, SGX Pharmaceuticals, IDM Pharma and Achillion Pharmaceuticals. |
| Lon Cardon |
Lon Cardon is the founder of Open Targets, Altius Institute For Biomedical Sciences. He is currently the President & Chief Executive Officer at The Jackson Laboratory and an Independent Director at Mirum Pharmaceuticals, Inc. Previously, he served as an Independent Director at Reneo Pharmaceuticals, Inc., Chief Scientific Strategy Officer at BioMarin Pharmaceutical, Inc., and Senior Vice President-Target Sciences at GSK Plc. He also held professorial positions at the University of Washington, the University of Oxford, and the Fred Hutchinson Cancer Research Center. Additionally, he was a member of the National Human Genome Research Institute. Dr. Cardon holds a doctorate from The University of Colorado and an undergraduate degree from the University of Puget Sound. |
| William C. Fairey |
Mr. William C. Fairey is an Independent Director at Aileron Therapeutics, Inc., an Independent Director at Ascendis Pharma A/S, an Executive Chairman at Respira Therapeutics, Inc. and an Independent Director at Mirum Pharmaceuticals, Inc. He is on the Board of Directors at KalVista Pharmaceuticals, Inc., Aileron Therapeutics, Inc., Ascendis Pharma A/S, Mirum Pharmaceuticals, Inc. and Actelion Pharmaceuticals Trading (Shanghai) Co. Ltd. Mr. Fairey was previously employed as a Chief Commercial Officer & Executive VP by MyoKardia, Inc., a Chief Operating Officer & Executive Vice President by ChemoCentryx, Inc., a President by Actelion Pharmaceuticals US, Inc., a Regional Vice President-Australia Asia Pacific by Actelion Pharmaceuticals Ltd., a President by Actelion Pharmaceuticals Canada, Inc., and a Regional Vice President by Australia Asia Pacific Hotels Ltd. He also served on the board at Lung Therapeutics LLC. He received his undergraduate degree from the University of Oregon and an MBA from St. Mary's College of California. |
| Sona Saira Ramasastry |
Sona Saira Ramasastry is the founder of Life Sciences Advisory LLC, which was founded in 2009. She currently holds several positions as an independent director or member of the board of directors, including at Glenmark Pharmaceuticals Ltd., Vir Biotechnology, Inc., Mirum Pharmaceuticals, Inc., Pain Therapeutics, Inc., Elevian, Inc., DOT Therapeutics-2, Inc., and Day One Biopharmaceuticals, Inc. She is also a member of the Aspen Global Leadership Network and the European Prevention of Alzheimer's Dementia Consortium. Ms. Ramasastry has held former positions as an independent director at Repros Therapeutics, Inc., Sangamo Therapeutics, Inc., Cassava Sciences, Inc., and 9 Meters Biopharma, Inc. She was also a financial analyst at Wasserstein Perella & Co., Inc. in 1997-1998. Ms. Ramasastry received her undergraduate and graduate degrees from Stanford University and her graduate degree from the University of Cambridge. |
| Patrick J. Heron |
Patrick J. Heron was the founder of QuatRx Pharmaceuticals Co. (founded in 2000) and held the title of Director from 2012 to 2017. He currently holds multiple positions, including Chairman at Arcutis Biotherapeutics, Inc. (since 2019), and Director at VentiRx Pharmaceuticals, Inc., Amunix, Inc., Zavante Therapeutics, Inc., Scout Bio, Inc., Iterum Therapeutics International Ltd., Iterum Therapeutics US Holding Ltd., Recida Therapeutics, Inc., Mirum Pharmaceuticals, Inc., MBX Biosciences, Inc., HilleVax, Inc., and Calibrium LLC. He is also the Managing Partner at Frazier Management LLC (since 1999). In his former roles, Mr. Heron served as Chairman at Kalidex Pharmaceuticals, Inc. (2012-2013), and held director positions at Panomics LLC, Chimerix, Inc., Avera Pharmaceuticals, Inc., Emergent Product Development Seattle (2002-2010), Informed Medical Communications, Inc., Collegium Pharmaceutical, Inc. (2008-2016), Cerexa, Inc. (2005-2007), Marcadia Biotech, Inc. (2006-2010), Calixa Therapeutics, Inc. (2007-2009), PreCision Dermatology, Inc., Silvergate Pharmaceuticals, Inc. (2011-2019), MedPointe, Inc. (2001-2007), Tobira Therapeutics, Inc., Moximed, Inc., Ignyta, Inc., ARMO BioSciences, Inc., Cidara Therapeutics, Inc. (2014-2015), Imago BioSciences, Inc. (2014-2022), Tobira Therapeutics, Inc. (2015-2016), Vaxcyte, Inc. (2017-2021), Iterum Therapeutics Plc (2015-2021), and Passage Bio, Inc. (2018-2021). Mr. Heron's education includes an undergraduate degree from The University of North Carolina at Chapel Hill (1992) and an MBA from Harvard Business School (1996). |
| Laurent Fischer |
Dr. Laurent Fischer, MD, is a President, Chief Executive Officer & Director at Adverum Biotechnologies, Inc., an Independent Director at Mirum Pharmaceuticals, Inc., a Chairman at CTI BioPharma Corp. and an Independent Director at Lycia Therapeutics, Inc. He is on the Board of Directors at Adverum Biotechnologies, Inc., Mirum Pharmaceuticals, Inc., Lycia Therapeutics, Inc. and dpa Deutsche Presse-Agentur GmbH.
Dr. Fischer was previously employed as an Independent Director by Senti Sub I, Inc., a Senior Advisor by Frazier Management LLC, a Senior Vice President by Allergan Ltd. (Ireland), a Chief Executive Officer by Tobira Therapeutics, Inc., a Chairman, President & Chief Executive Officer by Jennerex Biotherapeutics, Inc., a Chairman & Chief Executive Officer by Tobira Therapeutics, Inc. /Old/, a Vice Chairman by Ocera Therapeutics, Inc. /Old/, a Vice President-Corporate Development by MedVantx, Inc., a President & Chief Executive Officer by Auxeris Therapeutics, Inc., a President & Chief Operating Officer by Rxcentric, Inc., a Senior Vice President-Global Virology by DuPont Merck Pharmaceutical Co., a Senior Vice President-Global Virology by DuPont Pharmaceuticals Co., and a Medical Director-Virology Group by Hoffmann-La Roche, Inc. He also served on the board at Panacos Pharmaceuticals, Inc. and AIDS Healthcare Foundation.
He received his undergraduate degree from the University of Geneva and a doctorate degree from the University of Geneva. |
| Laura A. Brege |
Laura A. Brege currently works at Council on International Educational Exchange, Inc., as Chairman, ACADIA Pharmaceuticals, Inc., as Independent Director from 2008, Pacira Biosciences, Inc., as Independent Director from 2011, Pacira Pharmaceuticals, Inc. (California), as Director from 2011, Ohio University Foundation, as Director, HLS Therapeutics, Inc., as Independent Director from 2019, Edgewise Therapeutics, Inc., as Independent Non-Executive Director from 2020, Mirum Pharmaceuticals, Inc., as Independent Director from 2019, and T-Knife Therapeutics, Inc., as Director from 2021. Ms. Brege also formerly worked at Nodality, Inc., as President, Chief Executive Officer & Director from 2013 to 2015, Delcath Systems, Inc., as Independent Director from 2013 to 2014, Dynavax Technologies Corp., as Independent Director from 2015 to 2020, Angiotech Pharmaceuticals, Inc., as Director from 2007 to 2011, Portola Pharmaceuticals LLC, as Independent Director from 2015 to 2020, Zvents, Inc., as Director, Aratana Therapeutics, Inc., as Independent Director from 2014 to 2019, Avexus, Inc., as Director, The Bay Area Bioscience Association, as Independent Director, Cervantes Life Science Partners LLC, as Managing Director from 2015 to 2018, California Life Sciences Association, as Director, The Cooper Cos., Inc., as Treasurer & Vice President from 1982 to 1988, COR Therapeutics, Inc., as Chief Financial Officer & Senior Vice President from 1991 to 1999, Onyx Pharmaceuticals, Inc., as Chief Operating & Business Officer, Executive VP from 2006 to 2011, Flextronics Corp., as Chief Financial Officer & Vice President from 1988 to 1991, and Red Rock Capital Management, Inc., as General Partner from 1999 to 2008. Ms. Brege received her Masters Business Admin degree in 1982 from The University of Chicago, undergraduate degree in 1978 from The Ohio University, and Masters Business Admin degree from The University of Chicago Booth School of Business. |
| Timothy P. Walbert |
Timothy P. Walbert is currently the President & Chief Executive Officer at Horizon Therapeutics Plc and Horizon Therapeutics USA, Inc. He is also the Director at Biotechnology Innovation Organization, Pharmaceutical Research & Manufacturers of America, The Arthritis Foundation, Illinois Biotechnology Industry Organization, Horizon Pharmaceutical LLC, Exicure Operating Co., Chicagonext, Viela Bio, Inc., Mirum Pharmaceuticals, Inc., Century Therapeutics, Inc., Sagimet Biosciences, Inc., and a Trustee at Muhlenberg College. Additionally, he is a Member of the Illinois Innovation Council. In his former roles, Mr. Walbert served as the President & Chief Executive Officer at Hyperion Therapeutics, Inc., IDM Pharma, Inc., Horizon Therapeutics, Inc., and Horizon Pharma, Inc. He was also the Chairman at Zyla Life Sciences LLC, Co-Chairman at Innovation Development Institute, Inc., Chairman at Exicure, Inc., and Lead Independent Director at Assertio Therapeutics, Inc. Furthermore, he held positions as an Independent Director at XOMA Corp., Sucampo Pharmaceuticals LLC, Raptor Pharmaceuticals Corp., and Horizon Pharmaceutical LLC. He was a Director at World Business Chicago and held various roles at Celebrex North America, Abbott Laboratories, Wyeth LLC, Merck & Co., Inc., NeoPharm, Inc., and G.D. Searle & Co., Inc.
Mr. Walbert obtained his undergraduate degree from Muhlenberg College. |
